Cargando…

Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis

BACKGROUND: Cognitive impairment is one of the most important clinical features of neurodegenerative disorders including multiple sclerosis (MS). Conducted research shows that up to 65 percent of MS patients have cognitive deficits such as episodic memory, sustained attention, reduced verbal fluency...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Elżbieta, Morel, Agnieszka, Redlicka, Justyna, Miller, Igor, Saluk, Joanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018194/ https://www.ncbi.nlm.nih.gov/pubmed/29119933 http://dx.doi.org/10.2174/1570159X15666171109132650

Ejemplares similares

Novel Advances to Post-Stroke Aphasia Pharmacology and Rehabilitation
por: Cichon, Natalia, et al.
Publicado: (2021)

The Relationship between Cognitive Dysfunction and Postural Stability in Multiple Sclerosis
por: Redlicka, Justyna, et al.
Publicado: (2021)

Th17-Related Cytokines as Potential Discriminatory Markers between Neuromyelitis Optica (Devic’s Disease) and Multiple Sclerosis—A Review
por: Maciak, Karina, et al.
Publicado: (2021)

The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients
por: Morel, Agnieszka, et al.
Publicado: (2016)

Impact of Moderate Individually Tailored Physical Activity in Multiple Sclerosis Patients with Fatigue on Functional, Cognitive, Emotional State, and Postural Stability
por: Redlicka, Justyna, et al.
Publicado: (2021)

Relationship between the Increased Haemostatic Properties of Blood Platelets and Oxidative Stress Level in Multiple Sclerosis Patients with the Secondary Progressive Stage
por: Morel, Agnieszka, et al.
Publicado: (2015)

Flow cytometric analysis reveals the high levels of platelet activation parameters in circulation of multiple sclerosis patients
por: Morel, Agnieszka, et al.
Publicado: (2017)

Pharmacological Interventions and Rehabilitation Approach for Enhancing Brain Self-repair and Stroke Recovery
por: Szelenberger, Rafał, et al.
Publicado: (2020)

Increased level of fibrinogen chains in the proteome of blood platelets in secondary progressive multiple sclerosis patients
por: Bijak, Michal, et al.
Publicado: (2019)

New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis
por: Zielińska-Nowak, Ewa, et al.
Publicado: (2020)

The Role of Supplementation with Natural Compounds in Post-Stroke Patients
por: Cichon, Natalia, et al.
Publicado: (2021)

Oxidative Damage of Blood Platelets Correlates with the Degree of Psychophysical Disability in Secondary Progressive Multiple Sclerosis
por: Dziedzic, Angela, et al.
Publicado: (2020)

A Review of Various Antioxidant Compounds and their Potential Utility as Complementary Therapy in Multiple Sclerosis
por: Miller, Elzbieta Dorota, et al.
Publicado: (2019)

The Level of Isoprostanes as a Non-invasive Marker for in vivo Lipid Peroxidation in Secondary Progressive Multiple Sclerosis
por: Miller, Elżbieta, et al.
Publicado: (2011)

Metformin as a Potential Agent in the Treatment of Multiple Sclerosis
por: Dziedzic, Angela, et al.
Publicado: (2020)

The GPR17 Receptor—A Promising Goal for Therapy and a Potential Marker of the Neurodegenerative Process in Multiple Sclerosis
por: Dziedzic, Angela, et al.
Publicado: (2020)

Isoprostanes and Neuroprostanes as Biomarkers of Oxidative Stress in Neurodegenerative Diseases
por: Miller, Elżbieta, et al.
Publicado: (2014)

miR-155 as an Important Regulator of Multiple Sclerosis Pathogenesis. A Review
por: Maciak, Karina, et al.
Publicado: (2021)

The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis
por: Dziedzic, Angela, et al.
Publicado: (2021)

The Molecular Aspects of Disturbed Platelet Activation through ADP/P2Y(12) Pathway in Multiple Sclerosis
por: Dziedzic, Angela, et al.
Publicado: (2021)

Unusual Bioactive Compounds with Antioxidant Properties in Adjuvant Therapy Supporting Cognition Impairment in Age-Related Neurodegenerative Disorders
por: Cichon, Natalia, et al.
Publicado: (2021)

Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
por: Pietrasik, Sylwia, et al.
Publicado: (2021)

Increased Pro-Thrombotic Platelet Activity Associated with Thrombin/PAR1-Dependent Pathway Disorder in Patients with Secondary Progressive Multiple Sclerosis
por: Dziedzic, Angela, et al.
Publicado: (2020)

Variation of genes encoding nitric oxide synthases and antioxidant enzymes as potential risks of multiple sclerosis development: a preliminary study
por: Wigner, Paulina, et al.
Publicado: (2022)

Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review
por: Chen, Michelle H., et al.
Publicado: (2020)

Probiotics and Commensal Gut Microbiota as the Effective Alternative Therapy for Multiple Sclerosis Patients Treatment
por: Dziedzic, Angela, et al.
Publicado: (2022)

Pharmacological and non‐pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review
por: Blackman, Jonathan, et al.
Publicado: (2020)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis
por: Dighriri, Ibrahim M, et al.
Publicado: (2023)

Remyelination in multiple sclerosis from the miRNA perspective
por: Maciak, Karina, et al.
Publicado: (2023)

Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2021)

The influential factors and non-pharmacological interventions of cognitive impairment in children with ischemic stroke
por: Xu, Gang, et al.
Publicado: (2022)

Neurodegeneration in Niemann–Pick Type C Disease: An Updated Review on Pharmacological and Non-Pharmacological Approaches to Counteract Brain and Cognitive Impairment
por: Cariati, Ida, et al.
Publicado: (2021)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
por: Wiendl, Heinz, et al.
Publicado: (2015)

Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis
por: Saluk-Bijak, Joanna, et al.
Publicado: (2019)

Impaired cognition and attention in adults: pharmacological management strategies
por: Allain, Hervé, et al.
Publicado: (2007)

Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits
por: Russo, Mirella, et al.
Publicado: (2022)

Effects of non-pharmacological or pharmacological interventions on cognition and brain plasticity of aging individuals
por: Pieramico, Valentina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_60l9eja1r3ig24pmjgijdf4qha